Can BioNTech’s Ambitious Move into Cancer Therapy Save Its Future?
BioNTech faces challenges as COVID-19 vaccine revenue declines, with earnings per share dropping from €1.90 to €1.08. To combat financial downturn, BioNTech is investing heavily in mRNA-based cancer therapies, leading…